Organization
Eli Lilly & Company, Indianapolis, United States
3 abstracts
Abstract
BARICITINIB EFFECTS ON SERUM CHOLESTEROL AND CIRCULATING LIPID PARTICLES IN A PHASE 2B STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS Org: Eli Lilly & Company, Indianapolis, United States,
Abstract
BARICITINIB EFFECTS ON LIPID AND NMR-MEASURED LIPOPROTEIN PROFILES IN A PHASE 3 STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS Org: Quintiles Transnational INC, Durham, Eli Lilly & Company, Indianapolis, United States,
Abstract
BARICITINIB, AN ORAL JANUS KINASE (JAK)1/JAK2 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO TNF INHIBITORS: RESULTS OF THE PHASE 3 RA-BEACON STUDY Org: Stanford University School of Medicine, Albany Medical College, Rheumazentrum Favoriten, East Penn Rheumatology, Eli Lilly & Company, Indianapolis, United States,